Current Treatment Options in Neurology

, Volume 8, Issue 3, pp 224–235

Initial treatment of parkinson’s disease

  • Daniel Tarsy

Opinion statement

Initial treatment of early idiopathic Parkinson’s disease (PD) begins with diagnosis based on clinical evaluation supplemented by laboratory studies and brain imaging to exclude causes of secondary parkinsonism. In most cases, testing is normal and the diagnosis of PD rests on clinical criteria. In patients with mild symptoms and signs, the diagnosis of PD may not initially be apparent, and follow-up evaluation is needed to arrive at a diagnosis. Once the diagnosis is made, pharmacologic treatment may not be the first step. First, patient education is essential, especially because PD is a highprofile disease for which information and misinformation are readily available to patients and families. Counseling concerning prognosis, future symptoms, future disability, and treatment must be provided. Questions from patients concerning diet, lifestyle, and exercise are especially common at this point. The decision of when to initiate treatment is the next major consideration. Much controversy but relatively little light has been brought to bear on this issue. L-dopa was the first major antiparkinson medication to be introduced and remains the “gold standard” of treatment. Next in efficacy are the dopamine agonists (DAs). A debate has raged concerning whether initial dopaminergic treatment should be with L-dopa or DAs. Physicians have been concerned about forestalling the appearance of dyskinesias and motor fluctuations, whereas patients have incorrectly understood that L-dopa and possibly other antiparkinson drugs have a finite duration of usefulness, making it important to defer treatment for as long as possible. This has created “L-dopa phobia,” which may stand in the way of useful treatment. In spite of this controversy, there is uniform agreement that the appropriate time to treat is when the patient is beginning to be disabled. This varies from patient to patient and depends on age, employment status, nature of job, level of physical activity, concern about appearance, and other factors. The choice of a specific drug is sometimes dictated by the patient’s symptoms. For example, L-dopa is preferable for severe akinesia, an anticholinergic may be useful when tremor is the most prominent symptom (especially in those aged younger than 70 years), and DAs may be indicated for younger patients, more prone to dyskinesias and fluctuations, with relatively mild symptoms. It is also important to manage non-motor symptoms in patients with early PD. Anxiety and depression are particularly common at this stage and may be presenting symptoms of PD. Where appropriate, counseling and/or treatment with anxiolytics and antidepressants should be considered.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Olanow CW, Watts RL, Koller WC: An algorithm (decision tree) for the management of Parkinson’s disease (2001): treatment guidelines. Neurology 2001, 56(Suppl 5):S1-S88. A comprehensive, high-quality guide to treatment of early and more advanced PD.PubMedGoogle Scholar
  2. 2.
    Tarsy D: Diagnostic criteria for Parkinson’s disease. In Parkinson’s Disease. Edited by Ebadi M, Pfeiffer R. Boca Raton, FL: CRC Press; 2005:569–578.Google Scholar
  3. 3.
    Hughes AJ, Daniel SE, Kilford L, Lees AJ: Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992, 55:181–184.PubMedGoogle Scholar
  4. 4.
    Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ: The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002, 125:861–870.PubMedCrossRefGoogle Scholar
  5. 5.
    Schults CW, Oakes D, Kieburtz K, et al.: Effects of coenzyme Q10 in early Parkinson disease. Arch Neurol 2002, 59:1541–1550.CrossRefGoogle Scholar
  6. 6.
    Goetz CG, Koller WC, Poewe W, et al.: Management of Parkinson’s disease: an evidence-based review. Mov Disord 2002, 17(Suppl 4):S156-S159. This is an authoritative, evidence-based review of all treatment modalities used in PD.Google Scholar
  7. 7.
    Ellis T, de Goede CJ, Feldman RG, et al.: Efficacy of a physical therapy program in patients with Parkinson’s disease: a randomized controlled trial. Arch Phys Med Rehabil 2005, 86:626–632.PubMedCrossRefGoogle Scholar
  8. 8.
    Rubinstein PC, Giladi N, Hausdorff JM: The power of cueing to circumvent dopamine deficits: a review of physical therapy treatment of gait disturbances in Parkinson’s disease. Mov Disord 2002, 17:1148–1160.PubMedCrossRefGoogle Scholar
  9. 9.
    Cristian A, Katz M, Cutrone E, Walker RH: Evaluation of acupuncture in the treatment of Parkinson’s disease: a double-blind pilot study. Mov Disord 2005, 20:1185–1188.PubMedCrossRefGoogle Scholar
  10. 10.
    Ramig LO, Countryman S, O’Brien C, et al.: Intensive speech treatment for patients with Parkinson’s disease: short- and long-term comparison of two techniques. Neurology 1996, 47:1496–1504.PubMedGoogle Scholar
  11. 11.
    Ravina BM, Fagan SE, Hart RG, et al.: Neuroprotective agents for clinical trials in Parkinson’s disease. Neurology 2003, 60:1234–1240.PubMedGoogle Scholar
  12. 12.
    Schapira AHV, Olanow CW: Neuroprotection in Parkinson disease. Mysteries, myths, and misconceptions. JAMA 2004, 291:358–364. A useful overview of the methodologic problems of assessing potential neuroprotective agents.PubMedCrossRefGoogle Scholar
  13. 13.
    Ives NJ, Stowe RL, Marro J, et al.: Monoamine oxidase type B inhibitors in early Parkinson’s disease: metaanalysis of 17 randomized trials involving 3,525 patients. BMJ 2004, 329:593–596.PubMedCrossRefGoogle Scholar
  14. 14.
    Waters CH: Fluoxetine and selegiline--lack of significant interaction. Can J Neurol Sci 1994, 21:259–261.PubMedGoogle Scholar
  15. 15.
    Toyana SC, Iacono RP: Is it safe to combine a selective serotonin reuptake inhibitor with selegiline? Ann Pharmacother 1994, 28:405.Google Scholar
  16. 16.
    Richard IH, Kurlan R, Tanner C, et al.: Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson’s disease. Neurology 1997, 48:1070–1077.PubMedGoogle Scholar
  17. 17.
    Thorogood M, Armstrong B, Nichols T, Hollowell J: Mortality in people taking selegiline: observational study. BMJ 1998, 317:252–254.PubMedGoogle Scholar
  18. 18.
    Marras C, McDermott NP, Rochon PA, et al.: Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohorts. Neurology 2005, 64:87–93.PubMedGoogle Scholar
  19. 19.
    Luginger B, Wenning TK, Bosch S, Poewe W: Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson’s disease. Mov Disord 2000, 15:873–878.PubMedCrossRefGoogle Scholar
  20. 20.
    Katzenschlager R, Sampaio C, Costa J, Lees A: Anticholinergics for symptomatic management of Parkinson’s disease. Cochrane Database Syst Rev 2003, CD003735.Google Scholar
  21. 21.
    Rascol O, Brooks DJ, Korczyn AD, et al.: A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who have been treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000, 342:1484–1491.PubMedCrossRefGoogle Scholar
  22. 22.
    Holloway RG, Shoulson I, Fahn S, et al.: Pramipexole vs levodopa as initial treatment for Parkinson disease: a four-year randomized controlled trial. Arch Neurol 2004, 61:1044–1053.PubMedCrossRefGoogle Scholar
  23. 23.
    Frucht S, Rogers JD, Greene PE, et al.: Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999, 52:1908–1910.PubMedGoogle Scholar
  24. 24.
    Driver-Dunckley E, Samanth A, Stacy M: Pathological gambling associated with dopamine agonist therapy in Parkinson’s disease. Neurology 2003, 61:422–423.PubMedGoogle Scholar
  25. 25.
    Pritchett AM, Morrison JF, Edwards W, et al.: Valvular heart disease in patients taking pergolide. Mayo Clin Proc 2002, 77:1280–1286.PubMedCrossRefGoogle Scholar
  26. 26.
    Parcopa: A rapidly dissolving formulation of carbidopa/ levodopa. Med Lett Drug Ther 2005, 47:12.Google Scholar
  27. 27.
    Koller WC, Hutton JT, Tolosa E, et al.: Immediate-relief and controlled-relief carbidopa/levodopa in Parkinson’s disease. A five-year randomized multicenter study. Neurology 1999, 53:1012–1019.PubMedGoogle Scholar
  28. 28.
    Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson’s disease in DATATOP patients requiring levodopa. Ann Neurol 1996, 39:37–45.Google Scholar
  29. 29.
    Olanow CW: Oxidation reactions in Parkinson’s disease. Neurology 1990, 40(Suppl 3):32–37.PubMedGoogle Scholar
  30. 30.
    Weiner WJ: Initial treatment of Parkinson disease. Levodopa or dopamine agonist. Arch Neurol 2004, 61:1966–1969.PubMedCrossRefGoogle Scholar
  31. 31.
    Agid Y, Chase T, Marsden CD: Adverse reactions to levodopa: drug toxicity or progression of disease? Lancet 1998, 351:851–852.PubMedCrossRefGoogle Scholar
  32. 32.
    The Parkinson Study Group: Levodopa and the progression of Parkinson’s disease. N Engl J Med 2004, 351:2498–2508.CrossRefGoogle Scholar
  33. 33.
    Olanow CW, Agid Y, Mizuno Y, et al.: Levodopa in Parkinson’s disease: Current controversies. Mov Disord 2004, 19:997–1005.PubMedCrossRefGoogle Scholar
  34. 34.
    Miyasaki J, Martin W, Suchowersky O, et al.: Practice parameter: initiation of treatment for Parkinson’s disease: an evidence-based review. Neurology 2002, 58:11–17.PubMedCrossRefGoogle Scholar
  35. 35.
    Nutt JG: Catechol-O-methyltransferase inhibitors for treatment of Parkinson’s disease. Lancet 1998, 51:1221–1222.CrossRefGoogle Scholar
  36. 36.
    Olanow CW, Kieburtz K, Stern M, et al.: Double-blind, placebo-controlled study of entacapone in levodopatreated patients with stable Parkinson disease. Arch Neurol 2004, 61:1563–1568.PubMedCrossRefGoogle Scholar
  37. 37.
    Olanow CW, Tasmar Advisory Panel: Tolcapone and hepatotoxic effects. Arch Neurol 2000, 57:263–267. A thorough and realistic appraisal of the actual risk associated with use of tolcapone.PubMedCrossRefGoogle Scholar
  38. 38.
    Pfeiffer RF, Botis-Wollmer I: Parkinson’s Disease and Nonmotor Dysfunction. Totowa, NJ: Humana Press; 2005. A comprehensive reference dedicated to the relatively neglected area of non-motor aspects of PD.Google Scholar
  39. 39.
    Hobson DE, Lang AE, Martin WRL: Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA 2002, 287:455–463.PubMedCrossRefGoogle Scholar
  40. 40.
    Razmy A, Lang AE, Shapiro CN: Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists. Arch Neurol 2004, 61:97–102.PubMedCrossRefGoogle Scholar
  41. 41.
    Dell’Agnello G, Ceravello R, Nuti A, et al.: SSRIs do not worsen Parkinson’s disease: evidence from an openlabel, prospective study. Clin Neuropharmacol 2001, 24:221–227.PubMedCrossRefGoogle Scholar
  42. 42.
    Parkinson Study Group: A controlled trial of rasagiline in early Parkinson disease. Arch Neurol 2002, 59:1937–1943.CrossRefGoogle Scholar
  43. 43.
    Parkinson Study Group: A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson’s disease and motor fluctuations. Arch Neurol 2005, 62:241–248.CrossRefGoogle Scholar
  44. 44.
    Parkinson Study Group: A controlled trial of rotigotine monotherapy in early Parkinson’s disease. Arch Neurol 2003, 62:1721–1728.CrossRefGoogle Scholar
  45. 45.
    Waters CH, Sethi KD, Hauser RA, et al.: Zydis selegiline reduces off time in Parkinson’s disease patients with motor fluctuations: a three-month, randomized, placebo-controlled study. Mov Disord 2004, 19:426–432.PubMedCrossRefGoogle Scholar
  46. 46.
    Elm JJ, Goetz CG, Ravina B, et al.: A responsive outcome for Parkinson’s disease neuroprotection futility studies. Ann Neurol 2005, 57:197–203.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2006

Authors and Affiliations

  • Daniel Tarsy
    • 1
  1. 1.Department of NeurologyBeth Israel Deaconess Medical CenterBostonUSA

Personalised recommendations